Reference number : 236-2012-2013-Q2-00085, amendment number : , agreement type : G, recipient legal name : GRANTON, John T, recipient country : CA, recipient province : ON, recipient city : Toronto, recipient postal code : M5G 2C4, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 188289.0, agreement start date : 2012-10-01, agreement end date : 2015-09-30, description english : Randomized, double-blind, placebo-controlled, multi-center, proof of concept study to evaluate the effect of sildenafil citrate (Revatio) 20 mg TID on hemodynamics in patients with Portal- Pulmonary Arterial Hypertension (PPAH) Short title: Revatio Portal Pulmonary Arterial Hypertension  Trial (RePo1 trial), description french : Randomized, double-blind, placebo-controlled, multi-center, proof of concept study to evaluate the effect of sildenafil citrate (Revatio) 20 mg TID on hemodynamics in patients with Portal- Pulmonary Arterial Hypertension (PPAH) Short title: Revatio Portal Pulmonary Arterial Hypertension  Trial (RePo1 trial), expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2012-13 to 2015-16), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2012-13 à 2015-16), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada